Solazyme, Inc. (NASDAQ: SZYM), a leader in microalgae food ingredients, and Twinlab Corporation, a leading manufacturer and marketer of high quality, science-based, nutritional supplements, announced today the launch of Twinlab’s CleanSeries Veggie Protein Powder featuring Solazyme’s breakthrough algal protein ingredient. Solazyme’s whole algal protein is a vegan whole-food source, microalgae-derived, non-allergenic, and naturally rich in fiber, healthy lipids, and micronutrients. It has a neutral flavor profile that can be incorporated easily into products for protein fortification, and is a complete functional food containing at least 50 percent protein by weight and 15-20 percent dietary fiber. “We see the launch of the CleanSeries Veggie Protein Powder as a clear indicator of market demand for our algal based protein ingredient,” said Jean-Marc Rotsaert, Chief Operating Officer, Solazyme. “The market has never been stronger for a new source of quality protein that matches the emerging consumer demands and we look forward to continuing to innovate food ingredient solutions through our revolutionary platform.” Twinlab CleanSeriesSports Nutrition, one of Twinlab’s latest innovations, is a series unlike any other: it contains no artificial flavors, sweeteners, colors, or parabens, is part of NSF’s Tested & Certified program. It is further batch-tested for banned substances as part of HFL’s Informed Sport Program. “CleanSeries represents a new standard in sports nutrition, helping us serve athletes in search of “clean” supplements that don’t sacrifice performance for peace of mind,” said Marc Stover, Twinlab’s Director of Marketing. “Solazyme’s pure algal protein is truly a breakthrough whole food ingredient and we strongly believe there will be wide market adoption of the Veggie Protein Powder based on the qualities this new ingredient brings to it.” About Solazyme Solazyme, Inc. (SZYM) is a renewable oil and bioproducts company that transforms a range of low-cost plant-based sugars into high-value oils and innovative microalgal food ingredients. Headquartered in South San Francisco, Solazyme’s renewable products can replace or enhance oils derived from the world's three existing sources — petroleum, plants and animal fats. Initially, Solazyme is focused on commercializing its products into three target markets: (1) fuels and chemicals, (2) nutrition and (3) skin and personal care.
Solazyme®, the Solazyme logo and other trademarks or service names are trademarks of Solazyme, Inc.About Twinlab Twinlab Corporation is a leading manufacturer and marketer of high quality, science-based, nutritional supplements, including a complete line of vitamins, minerals, nutraceuticals, herbs and sports nutrition products. Since 1968, the Twinlab brand has manufactured and marketed nutritional supplements in both the vitamin and sports nutrition categories. In addition to its namesake brand, Twinlab Corporation also manufactures and sells other well-known category leaders including the Metabolife® line of diet and energy products; Twinlab Fuel® line of sports supplement products; Alvita® teas, established in 1922 as a single-herb tea line; and Nature’s Herbs®, a complete line of herbals and phytonutrients. Twinlab’s manufacturing facility in American Fork, Utah is a NSF GMP-registered facility. Twinlab also runs an R&D facility in Grand Rapids, Michigan; and has its corporate headquarters in New York, NY. Visit www.twinlab.com for more information. Forward Looking Statements This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Solazyme, including statements that involve risks and uncertainties concerning: commercialization plans for Solazyme’s microalgal food ingredients, market demands, and the performance and health benefits of the microalgal food ingredients. When used in this press release, the words “will”, “expects”, “intends” and other similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Solazyme, that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this press release due to a number of risks and uncertainties. Potential risks and uncertainties include, among others: Solazyme’s limited operating history; its limited history in commercializing products; implementation risk in deploying new technologies and products; and market acceptance of its products. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Solazyme. In addition, please refer to the documents that Solazyme, Inc. files with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q, as updated from time to time, for a discussion of these and other risks. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. Solazyme is not under any duty to update any of the information in this press release.